Clinical Trials Logo

Xanthomatosis, Cerebrotendinous clinical trials

View clinical trials related to Xanthomatosis, Cerebrotendinous.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06180057 Completed - Clinical trials for Cerebrotendinous Xanthomatoses

Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)

Start date: June 12, 2022
Phase: Phase 1
Study type: Interventional

Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Chenodeoxycholic acid capsules (250mg chenodeoxycholic acid) [dose: 1 x 02 capsules] versus Chenodeoxycholic acid leadiant 250 mg hard capsules (250mg chenodeoxycholic acid) [dose: 1 x 02 capsules] in healthy subjects under fasting conditions.

NCT ID: NCT05499026 Completed - Clinical trials for Cerebrotendinous Xanthomatoses

Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

Start date: December 9, 2014
Phase:
Study type: Observational

Retrospective study of CTX patients to investigate the safety and clinical efficacy of Chenodeoxycholic Acid

NCT ID: NCT04270682 Completed - CTX Clinical Trials

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

Start date: January 31, 2020
Phase: Phase 3
Study type: Interventional

The study is made up of two cohorts: a randomized double-blind crossover (placebo withdrawal with rescue) study among patients ≥ 16 years of age (adult cohort) and an open-label dose titration study among pediatric patients ≥1 month and <16 years of age (pediatric cohort)